Synthetic Biologics


Stock Update (NYSE MKT:SYN): Synthetic Biologics Inc’s Initiates SYN-010 Phase 2 Clinical Trial to Treat Irritable Bowel Syndrome with Constipation

Synthetic Biologics Inc (NYSE MKT:SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported the initiation …

Company Update (NYSE MKT:SYN): First Participant Dosed in Synthetic Biologics Inc’s Second Phase 2a Clinical Trial to Protect the Microbiome and Prevent C. difficile

Synthetic Biologics Inc (NYSE MKT:SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific  diseases, dosed the first participant …

H.C. Wainwright Reaffirms Buy On Synthetic Biologics, Sees 186% Upside

In a research report published today, H.C.

Maxim Remains Positive On Synthetic Biologics Following R&D Day

In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Synthetic Biologics (NYSE:SYN) with a $6 price target, after the company held an R&D day on …

Maxim Reaffirms Buy On Synthetic Bio Ahead Of Trimesta Presentation

In a research note released yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (NYSE:SYN) with a $6 price target …

Maxim Maintains Buy On Synthetic Biologics Following 2Q14 Results

In a research report published August 14, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (SYN) with a $6 price target, following the company’s second-quarter results, burning …

Maxim Reaffirms Buy On Synthetic Biologics; Sees 266% Upside For The Stock

In a research report published Friday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (SYN) with a $6 price target, which …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts